Fibrobiologics, Common Stock Stock Analysis
| FBLG Stock | 2.15 0.01 0.46% |
FibroBiologics, Common Stock is undervalued with Real Value of 4.97 and Target Price of 13.5. The main objective of FibroBiologics, Common stock analysis is to determine its intrinsic value, which is an estimate of what FibroBiologics, Common Stock is worth, separate from its market price. There are two main types of FibroBiologics, Common's stock analysis: fundamental analysis and technical analysis.
The FibroBiologics, Common stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and FibroBiologics, Common's ongoing operational relationships across important fundamental and technical indicators.
FibroBiologics, |
FibroBiologics, Stock Analysis Notes
About 24.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.55. FibroBiologics, Common had not issued any dividends in recent years. To learn more about FibroBiologics, Common Stock call the company at 281 651 5150 or check out https://www.fibrobiologics.com.FibroBiologics, Common Investment Alerts
| FibroBiologics, Common generated a negative expected return over the last 90 days | |
| FibroBiologics, Common has high historical volatility and very poor performance | |
| Net Loss for the year was (16.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| FibroBiologics, Common generates negative cash flow from operations | |
| FibroBiologics, Common has a poor financial position based on the latest SEC disclosures | |
| About 24.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: FibroBiologics Earns Buy Rating from Analysts at Rodman Renshaw |
FibroBiologics, Largest EPS Surprises
Earnings surprises can significantly impact FibroBiologics, Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-07 | 2024-06-30 | -0.09 | -0.02 | 0.07 | 77 | ||
2024-11-27 | 2024-09-30 | -0.0867 | -0.01 | 0.0767 | 88 |
FibroBiologics, Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.86 M.FibroBiologics, Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.39) | (1.46) | |
| Return On Capital Employed | (3.37) | (3.20) | |
| Return On Assets | (1.39) | (1.46) | |
| Return On Equity | (13.16) | (12.50) |
Management Efficiency
FibroBiologics, Common has return on total asset (ROA) of (0.6577) % which means that it has lost $0.6577 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6786) %, meaning that it created substantial loss on money invested by shareholders. FibroBiologics, Common's management efficiency ratios could be used to measure how well FibroBiologics, Common manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.46. The FibroBiologics, Common's current Return On Capital Employed is estimated to increase to -3.2. At this time, FibroBiologics, Common's Total Current Assets are most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Debt To Assets is estimated to increase to 2.41, while Total Assets are projected to decrease to roughly 6.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.04 | 0.04 | |
| Tangible Book Value Per Share | 0.04 | 0.04 | |
| Enterprise Value Over EBITDA | (59.00) | (61.95) | |
| Price Book Value Ratio | 754.60 | 792.33 | |
| Enterprise Value Multiple | (59.00) | (61.95) | |
| Price Fair Value | 754.60 | 792.33 | |
| Enterprise Value | 938.1 M | 1 B |
The decision-making processes within FibroBiologics, Common are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Return On Assets (0.66) | Return On Equity (2.68) |
Technical Drivers
As of the 18th of December 2024, FibroBiologics, Common shows the Mean Deviation of 4.93, coefficient of variation of (1,506), and Standard Deviation of 6.39. FibroBiologics, Common technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm FibroBiologics, Common standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if FibroBiologics, Common is priced favorably, providing market reflects its regular price of 2.15 per share. Please also check FibroBiologics, Common Stock jensen alpha, which is currently at (0.66) to verify the company can sustain itself at a future point.FibroBiologics, Common Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. FibroBiologics, Common middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for FibroBiologics, Common. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
FibroBiologics, Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroBiologics, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroBiologics, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases FibroBiologics, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
O'heeron Pete over a week ago Disposition of 100000 shares by Oheeron Pete of FibroBiologics, Common subject to Rule 16b-3 | ||
O'heeron Pete over two weeks ago Disposition of 50000 shares by Oheeron Pete of FibroBiologics, Common subject to Rule 16b-3 | ||
Niklas Victoria Ninon Olivia over six months ago FibroBiologics Common exotic insider transaction detected | ||
Cilento Richard C Jr over six months ago FibroBiologics Common exotic insider transaction detected |
FibroBiologics, Common Predictive Daily Indicators
FibroBiologics, Common intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of FibroBiologics, Common stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 8292.5 | |||
| Daily Balance Of Power | (0.07) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 2.15 | |||
| Day Typical Price | 2.15 | |||
| Period Momentum Indicator | (0.01) |
FibroBiologics, Common Corporate Filings
F4 | 9th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of June 2024 Other Reports | ViewVerify | |
| 18th of June 2024 Other Reports | ViewVerify | |
| 17th of June 2024 Other Reports | ViewVerify |
FibroBiologics, Common Forecast Models
FibroBiologics, Common's time-series forecasting models are one of many FibroBiologics, Common's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary FibroBiologics, Common's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About FibroBiologics, Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how FibroBiologics, Common prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling FibroBiologics, shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as FibroBiologics, Common. By using and applying FibroBiologics, Stock analysis, traders can create a robust methodology for identifying FibroBiologics, entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current FibroBiologics, Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. FibroBiologics, analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. FibroBiologics, analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 13.5 | Strong Buy | 3 | Odds |
Most FibroBiologics, analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand FibroBiologics, stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of FibroBiologics, Common, talking to its executives and customers, or listening to FibroBiologics, conference calls.
FibroBiologics, Stock Analysis Indicators
FibroBiologics, Common Stock stock analysis indicators help investors evaluate how FibroBiologics, Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading FibroBiologics, Common shares will generate the highest return on investment. By understating and applying FibroBiologics, Common stock analysis, traders can identify FibroBiologics, Common position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 2.3 M | |
| Common Stock Shares Outstanding | 28.2 M | |
| Total Stockholder Equity | 1.3 M | |
| Property Plant And Equipment Net | 2.6 M | |
| Cash And Short Term Investments | 9.2 M | |
| Cash | 9.2 M | |
| Accounts Payable | 1.4 M | |
| Net Debt | -7.4 M | |
| 50 Day M A | 2.7782 | |
| Total Current Liabilities | 9.2 M | |
| Other Operating Expenses | 8.9 M | |
| Non Current Assets Total | 2.6 M | |
| Stock Based Compensation | 1.8 M |
Complementary Tools for FibroBiologics, Stock analysis
When running FibroBiologics, Common's price analysis, check to measure FibroBiologics, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroBiologics, Common is operating at the current time. Most of FibroBiologics, Common's value examination focuses on studying past and present price action to predict the probability of FibroBiologics, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroBiologics, Common's price. Additionally, you may evaluate how the addition of FibroBiologics, Common to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |